You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug [see all tables in this series...]

Part (iii) All clients with cocaine as primary drug type: number of episodes reporting the stated drugs as secondary

Country	Opioids	Cocaine	Other stimulants	Hypnotics/sedatives	Hallucinogens	Volatile substances	Cannabis	Alcohol	Others	Total
Czech Republic	0		0	0	0	0	1	1	0	2
Denmark	15	0	11	7	1	0	39	0	176	249
Germany	734	3554	933	239	306	12	1318	1525	37	8658
Ireland	42	6	117	25	1	1	141	111	0	444
Greece	18	2	18	7	9	0	38	7	1	100
France	138	17	87	32	15	4	188	89	8	578
Italy	996	39	427	91	37	19	2586	1249	85	5529
Cyprus	9	2	12	1	1		26			51
Malta	11		21	5	10	1	28			76
Netherlands	452	20	182	45	3	2	630	923	27	2284
Slovakia	1		1				1	1		4
Finland			1	1						2
United Kingdom	1528	414	595	195	38	5	1773	1759	35	6342
Total	3944	4054	2405	648	421	44	6769	5665	369	24319

Notes:

Data on secondary drug use are only collected among all treatment clients and not separately for new treatment clients.

'Opioids' include: heroin, methadone, other opioids; 'Cocaine' includes: cocaine HCl, crack cocaine; 'Stimulants' include: amphetamines, MDMA and derivates, other stimulants: 'Cannabis' can include herb or resin. For each client up to four secondary drugs can be reported.

A number of the clients report using the same drug both as primary and secondary drug, particularly for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI protocol for the drugs categories.

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

2006 Reitox national reports.